Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,207 public trials 1,003 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) Nashville, Tennessee, United States
  • Oncology Consultants (OC) - Texas Medical Center - Cancer Center Houston, Texas, United States
  • Shanghai East Hospital, Tongji University Shanghai, China
  • Tianjin Medical University Cancer Institute and Hospital Tianjin, China
View all 16 locations
View Trial Details
Recruiting

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

NCT07334119

Conditions
Adenocarcinoma, Adenocarcinoma Of Esophagus, Adnexal Diseases, +47 more
Locations
  • The Kinghorn Cancer Centre Darlinghurst, New South Wales, Australia
  • Scientia Clinical Research Ltd Randwick, New South Wales, Australia
  • Calvary Mater Newcastle Waratah, New South Wales, Australia
  • Icon Cancer Centre South Brisbane South Brisbane, Queensland, Australia
View Trial Details
Recruiting

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • UCLA Los Angeles, California, United States
  • UCI Chao Family Comprehensive Cancer Center Orange, California, United States
  • Georgetown University Medical Cener (GUMC) Washington D.C., District of Columbia, United States
  • Advent Health Orlando, Florida, United States
View all 33 locations
View Trial Details
Recruiting

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Carolina BioOncology Institute Huntersville, North Carolina, United States
  • Sarah Cannon Research Institute University of Oklahoma Oklahoma City, Oklahoma, United States
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +24 more
Locations
  • UCLA Santa Monica Hematology Oncology Santa Monica, California, United States
  • Winship Cancer Institute at Emory University Atlanta, Georgia, United States
  • Ochsner Health Jefferson, Louisiana, United States
  • START Midwest Grand Rapids, Michigan, United States
View all 20 locations
View Trial Details
Recruiting

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07594522

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) Commack, New York, United States
View Trial Details

Related conditions